VP, Head of New Products, Ophthalmology
Jehan Tamboowalla, is currently VP, Head of New Products, Ophthalmology at Novartis. Jehan brings more than 20 years of Product Launch, Commercial, and R&D experience spanning Ophthalmology, Immunology and Cell & Gene Therapies. Currently, Jehan and his team oversee commercial and marketing activities related to the Novartis Ophthalmology development pipeline. At Novartis, Jehan has been the worldwide commercial leader on numerous evaluations and transactions valued at over $6B in the last 24 months. Disclosed transactions include Lubris BioPharma (2017), Encore Vision (2017), Spark Therapeutics (2018), and Xiidra (lifitegrast ophthalmic solution) from Shire-Takeda (2019). Additionally, Jehan was also the first launch leader for Luxturna, a first in class gene therapy treatment for RPE65 deficient, retinitis pigmentosa. Novartis acquired the global (non-US) marketing rights from Spark Therapeutics in 2018. Before joining Novartis, Jehan was Managing Director at Red Team Associates, a boutique consulting firm, specialized in working with emerging biopharma, private equity, and venture capital clients. Preceding Red Team, Jehan’s industry experience includes multiple product launches and marketing roles of increasing responsibility at Bayer AG, Bausch & Lomb, and GSK. Jehan continues to mentor and advise leaders at emerging BioPharma and Biotech companies. Jehan holds BS and MS degrees in Biotechnology and Biology from the Worcester Polytechnic Institute, and an International MBA from the Thunderbird School of Global Management.
STAY UP TO DATE WITH OIS
Get the Latest News, Podcasts and Videos.